CA2829126A1 - Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections - Google Patents

Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections Download PDF

Info

Publication number
CA2829126A1
CA2829126A1 CA2829126A CA2829126A CA2829126A1 CA 2829126 A1 CA2829126 A1 CA 2829126A1 CA 2829126 A CA2829126 A CA 2829126A CA 2829126 A CA2829126 A CA 2829126A CA 2829126 A1 CA2829126 A1 CA 2829126A1
Authority
CA
Canada
Prior art keywords
lta
mimetic
synthetic
lipoteichoic acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2829126A
Other languages
English (en)
French (fr)
Inventor
Johannes Huebner
Andrea HUEBNER-KROPEC
Jeroen Dirk Cornelis Codee
Gijsbert Arie Van Der Marel
Wouter Frederik Johan HOGENDORF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Freiburg
Original Assignee
Universitaetsklinikum Freiburg
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Freiburg, Universiteit Leiden filed Critical Universitaetsklinikum Freiburg
Publication of CA2829126A1 publication Critical patent/CA2829126A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2829126A 2011-03-10 2012-02-17 Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections Abandoned CA2829126A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161451304P 2011-03-10 2011-03-10
US61/451,304 2011-03-10
EP20110157947 EP2500349B1 (en) 2011-03-11 2011-03-11 Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
EP11157947.0 2011-03-11
PCT/EP2012/052801 WO2012119846A1 (en) 2011-03-10 2012-02-17 Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections

Publications (1)

Publication Number Publication Date
CA2829126A1 true CA2829126A1 (en) 2012-09-13

Family

ID=43828266

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2829126A Abandoned CA2829126A1 (en) 2011-03-10 2012-02-17 Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections

Country Status (6)

Country Link
US (1) US9290531B2 (https=)
EP (1) EP2500349B1 (https=)
JP (1) JP6154751B2 (https=)
CA (1) CA2829126A1 (https=)
ES (1) ES2544808T3 (https=)
WO (1) WO2012119846A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US10781175B2 (en) 2016-07-15 2020-09-22 Am Chemicals Llc Solid supports and phosphoramidite building blocks for oligonucleotide conjugates
KR101950881B1 (ko) * 2017-08-10 2019-02-22 서울대학교산학협력단 리포테이코익산(Lipoteichoic acid(LTA))을 함유하는 피부 재생 및 창상 치유용 약학 조성물
MX394768B (es) * 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2208780C (en) * 1995-01-30 2010-03-30 Peter Truog Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747
AUPQ137699A0 (en) 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
WO2003066649A1 (en) * 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides

Also Published As

Publication number Publication date
US20140050741A1 (en) 2014-02-20
JP2014507450A (ja) 2014-03-27
EP2500349B1 (en) 2015-05-06
US9290531B2 (en) 2016-03-22
WO2012119846A1 (en) 2012-09-13
HK1175786A1 (en) 2013-07-12
ES2544808T3 (es) 2015-09-04
JP6154751B2 (ja) 2017-06-28
EP2500349A1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
Kusumoto et al. Key structures of bacterial peptidoglycan and lipopolysaccharide triggering the innate immune system of higher animals: chemical synthesis and functional studies
US20140170151A1 (en) Synthetic Oligosaccharides for Staphylococcus Vaccine
CA2843908C (en) Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccaride ps-i, methods of synthesis and uses thereof, in particular as vaccines anddiagnostic tools
US9290531B2 (en) Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
US9815889B2 (en) Antibodies for prevention and treatment of diseases caused by clostridium difficile
US9005622B2 (en) Cell wall components of enterococci and uses thereof
US9447133B2 (en) Synthetic oligosaccharides for moraxella vaccine
HK1175786B (en) Synthetic lta mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
US9255157B2 (en) Rhamno-polysaccharide from Enterococcus faecium clonal complex 17 and uses thereof
Østerlid Synthesis, structure and epitope mapping of well-defined Staphylococcus aureus capsular polysaccharides
WO2018155051A1 (ja) リピドａ
HK1178803B (en) Enterococcal cell wall components and antibacterial use thereof
DK2644613T3 (en) Cell wall polymers from Enterococcus faecalis and applications thereof

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180219